Aravive (NASDAQ:ARAV) achieved full enrollment in a global registrational Phase 3 trial of batiraxcept plus paclitaxel for platinum-resistant ovarian cancer (PROC).
The Phase 3 AXLerate-OC trial is evaluating efficacy and tolerability of 15 mg/kg batiraxcept in combination with weekly paclitaxel versus placebo in combination with weekly paclitaxel.
The trial was planned to enroll approximately 350 patients with platinum resistant, high grade serous ovarian cancer who received one-to-four prior lines of therapy at approximately 165 sites in the U.S. and Europe.
“Public reporting of topline data remains on track for mid-2023 and, if successful, are expected to support a biologics license application for PROC at the end of 2023,” Scott Dove, Ph.D. and COO of Aravive, said in a statement.
